Molecular Therapies in Hematology

• Applicant: Professor Dr. Michael Heuser
• Subject Area: Hematology, Oncology
• Term: from 2014 to 2021
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 258445828

• Final Report Year: 2021

No abstract available

Publications

• Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate. Leukemia, Vol. 30. 2016, pp. 1708–1715.
  Chaturvedi A., Araujo Cruz M.M., Jyotsana N., Sharma A., Goparaju R., Schwarzer S., Görlich K., Schottmann R., Struys E.A,. Jansen E.E., Rohde C., Müller-Tidow C., Geffers R., Göhring G., Ganser G., Thol F., Heuser M.
  
• Genomic Clas-sification and Prognosis in Acute Myeloid Leukemia. New England Journal of Medicine, Vol. 374. 2016, pp. 2209-2221.
  Papaemmanuil E., Gerstung M., Bullinger L., Gaidzik V., Paschka P., Potter N., Heuser M., Thol F., Bolli N., Gundem G., Van Loo P., et.al.
  
• RNA interference efficiently targets human leu-kemia driven by a fusion oncogene in vivo. Leukemia, Vol. 32. 2017, pp. 224-226.
  Jyotsana N, Sharma A, Chaturvedi A, Scherr M, Ku-chenbauer F, Sajti L, Barchanski A., Lindner R., Noyan F., Sühs K.W., Grote-Koska D., Brand K., Vornlocher H.P., Stanulla M., Bornhauser B., Bourquin J.P., Eder M., Thol F., Ganser A., Humphries R.K., Ramsay E., Cullis P., Heuser M.
  
• Measurable residual disease (MRD) monitoring by NGS before allogeneic hematopoietic cell transplantation in AML. Blood, Vol. 132. 2018, Issue 16, pp. 1703–1713.
  Thol F., Gabdoulline R., Liebich A., Klement P., Schiller J., Kandziora C., Hambach L., Stadler M., Koenecke C., Flintrop M., Pankratz M., Wichmann M., Paschka P., Döhner K., Döhner H., Ganser A., Heuser M., et al.
  
• Effective drug treatment identified by in vivo screening in a transplantable patient-derived xenograft model of chronic myelomonocytic leukemia. Leukemia, Vol. 34. 2020, Issue 11, pp. 2951–2963.
  Kloos A., Mintzas K., Winckler L., Gabdoulline R., Alwie Y., Jyotsana N., Kattre N., Schottmann R., Scherr M., Gupta C., Adams F.F., Schwarzer A., Heckl D., Schambach A., Imren S., Humphries R.K., Ganser A., Thol .F, Heuser M.
  
• In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site. Leukemia, Vol. 34. 2020, pp. 416–426.
  Chaturvedi A., Goparaju R., Gupta C., Weder J., Klunemann T., Araujo Cruz M.M., Kloos A., Goerlich K., Schottmann R., Othman B., Struys E.A., Bahre H., Grote-Koska D., Brand K., Ganser A,. Preller M., Heuser M.
  
• Meningioma 1 is indispensable for mixed lineage leukemia-rearranged acute myeloid leukemia. Haematologica, Vol. 105. 2020, No. 5, pp. 1294-1305.
  Sharma A., Jyotsana N., Gabdoulline R., Heckl D., Kuchenbauer F., Slany R.K., Ganser A., Heuser M.
  
• IDH1/2 mutations in acute myeloid leukemia patients and risk of coronary artery disease and cardiac dysfunction-a retrospective propensity score analysis. Leukemia, Vol. 35. 2021, pp. 1301–1316.
  Kattih B., Shirvani A., Klement P., Garrido A.M., Gabdoulline R., Liebich A., Brandes M., Chaturvedi A., Seeger T., Thol F., Gohring G., Schlegelberger B., Geffers R., John D., Bavendiek U., Bauersachs J., Ganser A., Heineke J., Heuser M.